April 23, 2014
Senior Manager Hideo Ienaka Astellas Pharma aims to become the number one player in the sodium-glucose co-transporter 2 (SGLT-2) inhibitor market with the first-in-class type 2 diabetes treatment Suglat (ipragliflozin). Suglat sales for a three day period after its debut...read more